Fundz
You are reading one round. Fundz also knows which of your own LinkedIn connections can open this account.See it live →

Adaptive raises $30 million in Series B funding led by Tidemark to enhance its agentic accounting platform for construction.

PUBLIC · ADPTSep 17, 2026•about 3 hours ago

Amount Raised

$30 Million

Round Type

Series B

SeattleBiotechnologyHealth CareTherapeutics

Investors

3 KvcDefinitionPathlightAndreessen HorowitzEmergence CapitalTidemark

Description

Adaptive has announced it secured $30 million in Series B funding, led by Tidemark. The funding will help accelerate the expansion of its Project Accounting Agents for various construction accounting needs. Participating investors include Emergence Capital, Andreessen Horowitz, Pathlight, Definition, and 3KVC. This round brings Adaptive's total capital raised to $57 million.

Company Information

Company

Adaptive Biotechnologies Corporation

Location

Seattle, Washington, United States

About

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the adaptive immune system's biology to transform disease diagnosis and treatment. They develop clinical products aimed at diagnosing and treating diseases using advanced genetic techniques. Their flagship product, clonoSEQ®, is designed to detect minimal residual disease in various blood cancers. The company's innovative approach seeks to provide precise and effective solutions in the field of hematology.

Don't miss Adaptive Biotechnologies Corporation's next move

Get an email the moment Adaptive Biotechnologies Corporation raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Adaptive Biotechnologies Corporation's next move

See what Strategic adds

Funding Insights

Based on industry data
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Adaptive Biotechnologies Corporation raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.